|
The Immunohistochemistry Antibody Company
|
- Home
-
Products
- All Antibodies
- IHC-plus Antibodies
-
Services
- Immunohistochemistry Studies
- Tissue Cross-Reactivity Screening
- Distributors
-
Resources
- About our Tissue Bank
- Customer Support
- How to Buy
- IHC-plus Protocol
- LSBio Media
- Publications
- Antibody Reports
-
Company
- About LifeSpan
- Press Releases
- Holiday Schedule
- Contact Us
|
|
Endometrial Cancer Screen 2 Tissue Microarray - LS-SEMCA2
This tissue microarray is available for use in LSBio Immunohistochemistry Studies only.
|
|
| Catalog ID: |
LS-SEMCA2 |
| Product Name: |
Endometrial Cancer Screen 2 |
| Description: |
12 endometrial adenocarcinoma specimens with stage/grade, and 12 matched adjacent normal/non-neoplastic endometrial specimens |
| Format: |
FFPE |
| Category: |
Human Tumor and Matched Normal |
| QA/QC: |
H&E reviewed; IHC validated with a positive control antibody |
| Storage: |
Short term RT; Long term 4ºC |
| Clinical History: |
No |
| Tissue Marker: |
No |
| Stage/Grade: |
Yes |
| Core Diameter: |
1.5 mm |
| Core Thickness: |
4 µm |
| Cases: |
24 |
| Cores: |
24 |
| Slides Per Set: |
1 |
LS-SEMCA2 Tissue Microarray Map
Slide Number 1
| LABEL | | | 1 | 2 | 3 | 4 | 5 | 6 | | A | End | End | End | End | End | End | | B | End | End | End | End | End | End | | C | End | End | End | End | End | End | | D | End | End | End | End | End | End |
|
Diagnosis Type Legend| Benign non-neoplastic | Diseased | Inflammatory | Malignant | Metastatic | Tumor | Unknown |
Element Tissue LegendEndometrium (End);
LS-SEMCA2 Element Details
| Slide | Position | Related Elements | Species | Gender | Age | Tissue | Diagnosis | Diagnosis Type | TNM Tumor Classification | Tumor Stage |
|---|
| 1 | A1 | B1 | Human | F | 44 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | II |
| 1 | A2 | B2 | Human | F | 56 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | II |
| 1 | A3 | B3 | Human | F | 51 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | I-II |
| 1 | A4 | B4 | Human | F | 36 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | II-III |
| 1 | A5 | B5 | Human | F | 40 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N1M0 | II-III |
| 1 | A6 | B6 | Human | F | 60 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | II-III |
| 1 | B1 | A1 | Human | F | 44 y | Endometrium (End) | Matched adjacent normal | Benign non-neoplastic | | |
| 1 | B2 | A2 | Human | F | 56 y | Endometrium (End) | Matched adjacent normal | Benign non-neoplastic | | |
| 1 | B3 | A3 | Human | F | 51 y | Endometrium (End) | Matched adjacent normal | Benign non-neoplastic | | |
| 1 | B4 | A4 | Human | F | 36 y | Endometrium (End) | Matched adjacent normal | Benign non-neoplastic | | |
| 1 | B5 | A5 | Human | F | 40 y | Endometrium (End) | Matched adjacent normal | Benign non-neoplastic | | |
| 1 | B6 | A6 | Human | F | 60 y | Endometrium (End) | Matched adjacent normal | Benign non-neoplastic | | |
| 1 | C1 | D1 | Human | F | 49 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | II-III |
| 1 | C2 | D2 | Human | F | 45 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | III |
| 1 | C3 | D3 | Human | F | 46 y | Endometrium (End) | Adenocarcinoma | Malignant | T3N0M0 | III |
| 1 | C4 | D4 | Human | F | 51 y | Endometrium (End) | Adenocarcinoma | Malignant | T3N1M0 | III |
| 1 | C5 | D5 | Human | F | 53 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N1M0 | III |
| 1 | C6 | D6 | Human | F | 56 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | III |
| 1 | D1 | C1 | Human | F | 49 y | Endometrium (End) | Matched adjacent normal | Benign non-neoplastic | | |
| 1 | D2 | C2 | Human | F | 45 y | Endometrium (End) | Matched adjacent normal | Benign non-neoplastic | | |
| 1 | D3 | C3 | Human | F | 46 y | Endometrium (End) | Matched adjacent normal | Benign non-neoplastic | | |
| 1 | D4 | C4 | Human | F | 51 y | Endometrium (End) | Matched adjacent normal | Benign non-neoplastic | | |
| 1 | D5 | C5 | Human | F | 53 y | Endometrium (End) | Matched adjacent normal | Benign non-neoplastic | | |
| 1 | D6 | C6 | Human | F | 56 y | Endometrium (End) | Matched adjacent normal | Benign non-neoplastic | | |
Copyright © 2013 LifeSpan BioSciences, Inc. All Rights Reserved
